


## Stage IV lung carcinoma with *EGFR*-activating mutation



<sup>a</sup>ESMO-MCBS v1.1 score for new therapy/indication approved by the EMA since 1 January 2016. The score has been calculated by the ESMO-MCBS Working Group and validated by the ESMO Guidelines Committee.  
<sup>b</sup>Preferred option [187b].  
<sup>c</sup>ESMO-MCBS score for the combination of bevacizumab with gefitinib or erlotinib.  
<sup>d</sup>Not EMA-approved.

### LLCG/VZN annotations

1. Rebiopsy or cfDNA plasma testing only after 1<sup>st</sup> or 2<sup>nd</sup> generation EGFR-TKI as 1<sup>st</sup> line therapy